BioStock: Saniona and Cephagenix comment on their joint migraine programme

Last week, Danish biotech company Saniona announced the successful preclinical in vivo validation for a migraine treatment in the Cephagenix joint venture programme. BioStock reached out to Professor Jes Olesen, CEO of Cephagenix and Palle Christophersen, Executive Vice President, Research, Saniona, to learn more about the collaboration and the recent development milstone.

Read the interview with Jes Olesen and Palle Christophersen at biostock.se:

Saniona and Cephagenix comment on their joint migraine programme - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/